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combined. Results: Using pneumococcal vaccine only enables to achieve the 
targeted 15% reduction in cases, hospital occupancy or deaths at annual cov-
erage of respectively 76.9%, 81.0%, 57.1%, and at the lowest annual vaccination 
budget of respectively € 26, € 27 and € 19 million. If meningococcal type B vaccine 
were prioritized in a UMV program, pneumococcal vaccine should still be added 
to achieve the public health objective. In such scenario, the annual vaccination 
budget would amount to € 57, € 59 and € 48 million, at the maximum achievable 
coverage of 60% for meningococcal vaccine and pneumococcal coverage of 76.8%, 
80.8% and 47.9%. ConClusions: Pneumococcal vaccine on its own can achieve 
the targeted 15% reduction in disease burden at the lowest vaccination budget. 
Vaccination against pneumococcal disease should therefore be prioritized in a 
UMV program in Poland.
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objeCtives: Varicella is a common childhood disease caused by varicella-zoster 
virus (VZV). Annually it affects around 651,000 individuals with 42% consulting 
general practitioners and 0.5% being hospitalized with recent trend of increase 
in the United Kingdom (UK). This poses significant public health concern due to 
high infection rates and associated economic burden. In countries with routine 
varicella vaccination significant reduction in varicella burden was observed. This 
study assesses the cost-effectiveness of introducing varicella vaccination as an 
addition to the current childhood immunization schedule of mumps, measles and 
rubella (MMR) vaccine in the UK. Methods: An age-structured dynamic transmis-
sion model was fitted to VZV seroprevalence in the non-vaccinated population 
in the UK. The model simulated the evolution of varicella and herpes zoster with 
and without vaccination with a lifetime horizon. The vaccination strategy con-
sidered coverage and age at dose 1 (90%;1year) and 2 (80%;3years), and catch up 
at 12 years with 20% coverage. Costs and effects are discounted at 3.5%. Results: 
The Incremental Cost Effectiveness Ratio at 5 and 15 years post introduction of 
vaccination with high coverage were £6,012(95%CI:-370;13,221)/Quality-Adjusted 
Life-Year (QALY) and £6,431(95%CI:337;13,188)/QALY, respectively. There were 
significant savings for outpatient and hospitalization costs: £22,274,734 and 
£5,178,472 by year 5; £82,954,153 and £17,470,473 by year 15, respectively. Varicella 
cases avoided following 5 and 15 years post implementation of vaccination were 
399,604 (57.7%) and 655,232 (94.8%), respectively. ConClusions: Implementing 
varicella vaccination in the UK will reduce the disease burden both in terms of 
varicella cases and associated costs, and is likely to be cost-effective. However, 
high vaccination coverage is required to achieve high impact of vaccination. 
Depending on the evolution of the UK vaccination schedule, vaccination with 
either monovalent varicella vaccine or combination MMR+Varicella vaccine 
could be a suitable option for implementation of varicella vaccination as part of 
a national immunization program.
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objeCtives: Estonia is now considering adding a pneumococcal conjugate vac-
cine (PCV) in its national immunization program to help reduce the burden of 
invasive pneumococcal diseases, pneumonia and acute otitis media (AOM). In 
this cost-effectiveness analysis (CEA), we estimate the vaccine price under which 
vaccinating with the pneumococcal non-typeable Haemophilus influenzae protein 
D conjugate vaccine (PHiD-CV) is considered cost-effective compared to no vac-
cination. Methods: A static cohort model (Knerer et al. 2012) has been adapted 
for Estonia using local serotype distribution, disease incidence and direct medical 
costs. Vaccine efficacy assumptions come from large PCV randomized controlled 
trials. Base case parameters have been validated by an expert panel and other 
scenarios were explored in extensive sensitivity analyses. CEA perspective is a 
modified healthcare payer (only including parents’ sick leave costs). The cohort 
is vaccinated at 2, 4 and 12 months with 95% coverage and followed over a life-
time (5% annual discount). Results: Under base case assumptions, vaccinating a 
cohort of 14,021 infants in Estonia with PHiD-CV would prevent 3927 AOM-related 
outpatient visits, 248 myringotomies, 93 cases of pneumonia, 8 cases of meningitis 
and 3 deaths over the cohort’s lifetime. Total effectiveness results translate into 
533 quality-adjusted life years (QALYs) gained and € 706,242 saved in treatment 
costs (undiscounted). With a Gross Domestic Product (GDP) per capita of € 14,860 
in Estonia (2014), the program would then be considered highly cost-effective 
(discounted incremental cost-effectiveness ratio (ICER) < 1 GDP/capita) if the vac-
cine price is below € 28.69/dose (€ 51.38 and € 74.08/dose for 2 and 3 GDP/capita, 
respectively). Reducing base case net herd protection by half, discounting at 3% 
and accounting only for direct medical costs would result in highly cost-effective 
thresholds of € 21.47, € 56.20 and € 25.63/dose, respectively. ConClusions: Our 
model predicts that PCV vaccination would be highly cost-effective under € 28.69/
dose and cost-effective until € 74.08/dose in Estonia.
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objeCtives: Herpes zoster (HZ), caused by reactivation of varicella zoster virus, is 
characterized by dermatome-based rash and severe pain. Post-herpetic neuralgia 
may occur following HZ. The risk of HZ increases with older age and reduced 
immunity. HZ vaccine has been first approved for adults aged 60 years and 
four, cost-effectiveness in two, cost benefit in one, cost-utility in one and general 
cost in one. All studies demonstrated satisfactory economic results comparing OPAT 
to inpatient care however fragile methodology was observed in the majority of 
study. ConClusions: in this review OPAT was a strategy that saved resources with 
favorable outcome in terms of related infection and complications.
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objeCtives: HCV infection is a leading cause of chronic liver disease with long-
term complications - extensive fibrosis, cirrhosis and hepatocellular carcinoma. The 
objective of this study is to perform analysis of the cost of therapy of patients with 
chronic HCV - related cirrhosis in Bulgaria. Methods: It is a combined prospective 
and retrospective, real life observational study of 301 patients with chronic HCV 
infection and cirrhosis monitored in the University Hospital “Queen Joanna-ISUL” 
for 3-year period (2012-2014). Data on demographic, clinical characteristics and 
healthcare resources utilization (hospitalizations, highly-specialized interven-
tions, pharmacotherapy) was collected. Micro-costing approach was applied to 
evaluate the total medical costs. The points of view are that of the National Health 
Insurance Fund (NHIF), hospital and the patients. Collected cost data are from the 
NHIF and hospitals tariffs, patients, and from the positive dug list for medicines 
prices. Statistical processing was through descriptive statistics and Chi-squared 
test. Results: 76% of patients were male. 93% were diagnosed in grade A and B 
according to Child-Pugh classification. 97% reported complications, and almost all 
developed esophageal varices. 847 hospitalizations were recorded for 3 years period 
with average length of stay 17 days. The mortality rate of 7% was extremely high. 
The total direct medical costs for the observed cohort of patients for 3-year period 
accounted for 1,2 million BGN (0.6 million EURO) and average cost per patient per 
year is 1343 BGN (671 Euro). The proportion of cost paid by the NHIF is 2/3 to 1/3 
for the hospital and the patients. A statistically significant correlation between 
the age, follow-up, number of hospitalizations and the Child-Pugh stage was 
found. ConClusions: HCV-related cirrhosis is resource demanding and implicit 
high direct medical costs as it is related with lots of hospitalizations and leads to 
complications acquiring additional treatment.
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objeCtives: The aim of this study is to investigate the cost of treating recurrent 
Clostridium difficile infection in patients attending infectious disease clinics at 4 
hospitals in Sweden. Methods: Following approval by the Central Ethical Review 
Board in Stockholm patient records of 120 patients were used to record the resources 
used to treat the latest recurrent infection. Recurrence was defined as a new toxin-
positive Clostridium difficile infection within 12 weeks of the previous Clostridium 
difficile infection. The sample included 47 patients not hospitalized and 73 hos-
pitalized patients. All resources used were itemized and a point estimate of the 
associated costs calculated using the average of two or more pricelists from county 
councils in Sweden. Results: This study shows that the treatment costs at the four 
participating infectious disease clinics in Sweden for treating a single event of recur-
rent Clostridium difficile infection ranged from SEK 921 to SEK 278323. Median cost 
for non-hospitalized patients was SEK 5397 and for hospitalized patients SEK 68078. 
We found that the 10% of the patients with the highest resource use accounted 
for MSEK 2,38, or nearly 40% of the accumulated resource use of MSEK 6,25 used 
to treat the 120 studied patients. ConClusions: Significant costs are associated 
with treatment of recurrent Clostridium difficile infections, especially when hos-
pitalization is needed. Minimizing the need for hospitalization during treatment 
is the single most important objective when minimizing the economic burden of 
recurrent Clostridium difficile infection.
PIN43
the devIl Is Not so blacK as he Is PaINted – the future of 
ImmuNIZatIoN IN PolaNd
Borowiack E1, Garbacka M1, Borowiack M1, Zapalska A1, Wepsiec K2, Tronczynska D2, 
Ksiazek A2, Van Bellinghen L3, Van Vlaenderen I3, Schecroun N4
1NUEVO HTA CLP, Cracow, Poland, 2GSK Services Sp. z o. o., Warsaw, Poland, 3CHESS in Health, 
Ternat, Belgium, 4Keyrus Biopharma c/o GSK Vaccines, Wavre, Belgium
objeCtives: Considering the burden of meningococcal and pneumococcal disease 
in 0-5 years old children in Poland, we aimed at determining which vaccine(s) to 
prioritize for a Universal Mass Vaccination (UMV) program to reduce the burden 
by 15% at the lowest annual budget. Methods: A Pediatric Expert Group on the 
Immunization Program in Poland defined pneumococcal vaccines as a priority 
based on epidemiological data (high frequency with growing antibiotic resistance) 
but the need for prevention against meningococcal disease was also highlighted. 
A vaccine portfolio management model was adapted to the Polish situation, con-
sidering pneumococcal and meningococcal (type B and C) vaccines. This opti-
mization model determines the optimal combination of vaccines to achieve a 
targeted public health objective at the lowest annual vaccination budget. Disease 
incidences, treatment pathways, vaccine efficacies, and maximal achievable UMV 
coverages were derived from published sources and expert opinion. The public 
health goal was to reach a 15% reduction over 5 years in disease cases, hospital 
occupancy or deaths related to both pneumococcal and meningococcal disease 
